Literature DB >> 3261799

Synthesis, conformation, and immunosuppressive activity of a conformationally restricted cyclosporine lactam analogue.

J D Aebi1, D Guillaume, B E Dunlap, D H Rich.   

Abstract

Cyclosporine A (CsA, 1), an immunosuppressive cyclic undecapeptide, in apolar solvents adopts a II' beta-turn at the Sar3-MeLeu4 residues. [D-Proline3]Cs has been reported to be a nonimmunosuppressive analogue in which the II' beta-turn is retained. In order to determine if this loss of activity is caused by steric hindrance between the Cs analogue and its receptor or is caused by a change in the peptide conformation, an analogue that stabilizes a II' beta-turn has been synthesized, [lactam3,4]Cs. We also have studied the solution conformation of two other analogues, [D-MeAla3]Cs and [L-MeAla3]Cs. The conformations have been established by 1D difference NOE and 2D (NOESY or ROESY) NMR. The conformations of [lactam3,4]Cs and [D-MeAla3]Cs are indistinguishable from that of CsA in solution. [L-MeAla3]Cs was found to adopt a conformation with a cis amide bond between Sar3 and MeLeu4. The inhibition of concanavalin A stimulated thymocytes by CsA, [D-MeAla3]Cs, [L-MeAla3]Cs, and [lactam3,4]Cs gave IC50 values (nM) of 5, 6, 100, and 100, respectively. The weak immunosuppressive activity of [lactam3,4]Cs possessing the II' beta-turn suggests that the loss of activity for 4 is due to steric hindrance with the Cs receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261799     DOI: 10.1021/jm00117a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations.

Authors:  V J Hruby; F al-Obeidi; W Kazmierski
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

2.  Structure-based design of chimeric antigens for multivalent protein vaccines.

Authors:  S Hollingshead; I Jongerius; R M Exley; S Johnson; S M Lea; C M Tang
Journal:  Nat Commun       Date:  2018-03-13       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.